Verona Pharma Reports Positive Phase 2 Results with pMDI Formulation of Ensifentrine in COPD

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases

The Medicines Evaluation Unit was a major participating centre in a study with Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases.

This week, Verona has announced positive Phase 2 data with a pressurized metered-dose inhaler formulation of ensifentrine in patients with moderate to severe COPD for this study.

“Demonstrating this magnitude of improvement in lung function is exciting,” said Dave Singh, M.D., Professor of Clinical Pharmacology and Respiratory Medicine, Medicines Evaluation Unit, University of Manchester and Investigator in the study.

“Combined with ensifentrine’s unique dual mechanism of action and favourable efficacy and safety profile already demonstrated in multiple Phase 2 clinical trials via nebulizer and dry powder inhaler (“DPI”), these data strengthen its potential as a novel therapeutic for COPD.”

Read the full press release via this link.